You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Personalized Neural Stem Cell Therapy for Cancer
SBC: Falcon Therapeutics, Inc. Topic: NCATSPROJECT SUMMARY Glioblastoma (GBM) is an intractable cancer with an average survival time of 12 to 15 months. Treatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrier, but engineered neural stem cells (NSCs) hold great promise as GBM therapies because they selectively migrate to ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
LC-MS System to Determine the Molecular Mass of Synthesized Heparan and Chondroitin Sulfate Oligosaccharides
SBC: GLYCAN THERAPEUTICS CORPORATION Topic: 300This fast-track STTR application proposes to synthesize structurally defined heparan sulfate and chondroitin sulfate oligosaccharides for biological research. Glycan Therapeutics is a biotech company specialized in synthesizing sulfated carbohydrates using innovative enzyme-based methods. This proposal is focused on the synthesis of large authentic oligosaccharides in the size range of 10-mers to ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia
SBC: Arrevus, Inc. Topic: NIAIDBloodstream infections (BSIs) caused by Gram-negative bacterial pathogens are associated with significant morbidity and mortality due to the antibiotic-resistant nature of the pathogens. Infections caused by multi-drug resistant (MDR) bacterial pathogens result in substantial health and economic impact due to the lack of effective therapeutic options. This lack of treatment options is particularly ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Non-Invasive Physiologic Evaluation of Peripheral Arterial Disease
SBC: RFPi, Inc. Topic: NHLBIABSTRACT Peripheral Arterial Disease (PAD) is a substantial healthcare burden in the US (estimated andgt; 8M) and around the world (estimated andgt; 200M). In the aging population, over 24% with age andgt; 80 years have PAD. 50% of all patients with PAD are asymptomatic, and up to 40% of the remaining patients have atypical symptoms. The conventional ankle/brachial index (cABI) ratio is establishe ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
C.A.R.E.S.: A Mobile Health Program for Alcohol Risk Reduction for an Under-Served College Population
SBC: LIVE INSPIRED LLC Topic: 550Excessive alcohol use is the third-leading preventable cause of death in the U.S. with young adults ages 18-29 showing the highest rates of hazardous alcohol use. Community colleges serve over 12 million students, comprising 45% of all U.S. college students. Community college students (CCS) show rates of heavy alcohol use similar to students at traditional four-year residential (FYR) colleges, but ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Ultrasound-Based Device to Guide Treatment of Graft-Versus-Host-Disease using Skin Elasticity as a Biomarker
SBC: Microelastic Ultrasound Systems, Inc. Topic: NCIUltrasound-Based Device to Guide Treatment of Graft-Versus-Host-Disease using Skin Elasticity as a Biomarker 1 ABSTRACT Sclerotic chronic graft versus host disease (cGVHD) develops in 30 - 70% of allogenic Human Stem Cell Transplant (HCT) recipients and is associated with significant morbidity and mortality. GVHD is treated with immunosuppression, which puts patients at severe risk of infection. I ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Rapid assay for RNA targeted drugs: Instrumentation Supplement
SBC: NUBAD LLC Topic: 300DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II
SBC: BITE TECHNOLOGIES, LLC Topic: 300DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
A Quantitative Optical Sensor to Monitor Tumor Vascular Physiology
SBC: Zenalux Biomedical, Inc. Topic: 102DESCRIPTION provided by applicant In there were new cases of head and neck cancers HNC in the United States Early detection of new and locally recurrent cancers is clinically important to reduce not only cancer related mortality but also treatment associated morbidity as it impacts multiple organ functions including respiration olfaction hearing eating swallowing and speak ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p
SBC: AGILE SCIENCES, INC. Topic: NIAIDDESCRIPTION provided by applicant The leading cause of mortality in patients with cystic fibrosis CF is pulmonary failure from lung infections and the predominant organism isolated from these infections is the bacterium Pseudomonas aeruginosa Lung infections of CF patients persist over the lifetime of the patients and are impossible to eradicate due to the ability of bacteria to form biofi ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health